联营
载体(分子生物学)
复制(统计)
生物
成对比较
计算生物学
病毒载体
效价
慢病毒
计算机科学
重组DNA
基因
病毒学
人类免疫缺陷病毒(HIV)
遗传学
人工智能
病毒
病毒性疾病
作者
Guillaume Corre,Michel Dessainte,Jean‐Brice Marteau,B Dalle,David Fenard,Anne Galy
摘要
Nonreplicative recombinant HIV-1-derived lentiviral vectors (LV) are increasingly used in gene therapy of various genetic diseases, infectious diseases, and cancer. Before they are used in humans, preparations of LV must undergo extensive quality control testing. In particular, testing of LV must demonstrate the absence of replication-competent lentiviruses (RCL) with suitable methods, on representative fractions of vector batches. Current methods based on cell culture are challenging because high titers of vector batches translate into high volumes of cell culture to be tested in RCL assays. As vector batch size and titers are continuously increasing because of the improvement of production and purification methods, it became necessary for us to modify the current RCL assay based on the detection of p24 in cultures of indicator cells. Here, we propose a practical optimization of this method using a pairwise pooling strategy enabling easier testing of higher vector inoculum volumes. These modifications significantly decrease material handling and operator time, leading to a cost-effective method, while maintaining optimal sensibility of the RCL testing. This optimized "RCL-pooling assay" ameliorates the feasibility of the quality control of large-scale batches of clinical-grade LV while maintaining the same sensitivity.
科研通智能强力驱动
Strongly Powered by AbleSci AI